| Filed On | Filing |
|---|---|
| 05 Nov 2026 |
8-K: Regulation FD Disclosure
Delivering Novel Therapies for RAS/MAPK Pathway - Driven Cancers CORPORATE PRESENTATION NOVEMBER 2026 |
| 14 Oct 2026 |
8-K: Other Events
Introductory. Verastem, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) (i) an aggregate of 30,937,500 shares (the “Shares”) of its common stoc... |
| 14 Oct 2026 |
8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation +2 more
VS - 7375 : Potential Best - in - Class KRAS G12D (ON/OFF) Inhibitor R&D Update October 14, 2026 |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
AVMAPKI® FAKZYNJA® CO-PACK net product revenue of $25.1 million |
| 07 Aug 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more
This Amendment No. 3 to Note Purchase Agreement (this “Amendment”), dated as of the date first set forth above, is entered into by and among Verastem, Inc., a Delaware corporation (“Issuer”), the Persons listed on the signature pages her... |
| 23 Jun 2026 |
8-K: Regulation FD Disclosure; Other Events
VS - 7375 : Potential Best - in - Class KRAS G12D (ON/OFF) Inhibitor R&D Update Call June 23, 2026 |
| 17 Jun 2026 |
8-K: Regulation FD Disclosure; Other Events
Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in First-Line Metastatic Pancreatic Cancer |
| 26 May 2026 |
8-K: Submission of Matters to a Vote of Security Holders
The 2026 annual meeting of stockholders (the “Annual Meeting”) of Verastem, Inc. (the “Company”) was held in Needham, Massachusetts on May 21, 2026. At the Annual Meeting, the stockholders considered and acted upon the following proposals: |
| 07 May 2026 |
8-K: Regulation FD Disclosure
Delivering Novel Therapies for RAS/MAPK Pathway-Driven Cancers C O R P O R A T E P R E S E N T A T I O N M A Y 2 0 2 6 |
| 04 Mar 2026 |
8-K: Regulation FD Disclosure
Delivering Novel Therapies for RAS/MAPK Pathway-Driven Cancers C O R P O R A T E P R E S E N T A T I O N M A R C H 2 0 2 6 |
| 04 Feb 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Verastem Oncology Provides Preliminary Fourth Quarter and 2025 Revenue and Business Updates and Outlines 2026 Strategic Priorities for Novel Portfolio Targeting RAS/MAPK Pathway-Driven Cancers |
| 08 Jan 2026 |
8-K: Regulation FD Disclosure
Delivering Novel Therapies for RAS/MAPK Pathway - Driven Cancers CORPORATE PRESENTATION JANUARY 2026 |
| 31 Dec 2025 |
8-K: Regulation FD Disclosure; Other Events
Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer |
| 19 Dec 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
As we have discussed, your employment with Verastem, Inc. (the “Company”) will terminate, effective as of December 19, 2025 (the “Separation Date”). Please consider this letter as written notice under Paragraph 10 of your Employment Agre... |
| 17 Nov 2025 |
8-K: Other Events
Introductory. Verastem, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) (i) an aggregate of 8,543,794 shares (the “Shares”) of its common stock... |
| 04 Nov 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Achieved AVMAPKI™ FAKZYNJA™ CO-PACK net product revenue of $11.2 million |
| 23 Oct 2025 |
8-K: Regulation FD Disclosure; Other Events
Verastem Oncology Announces Encouraging Preliminary Data from Ongoing Phase 1/2a Dose Escalation Trial of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients with KRAS G12D Mutant Solid Tumors |
| 20 Oct 2025 |
8-K: Regulation FD Disclosure; Other Events
Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics’ Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma |
| 08 Sep 2025 |
8-K: Regulation FD Disclosure
Delivering Novel Therapies for RAS/MAPK Pathway Driven Cancers Corporate Presentation | September 2025 |
| 13 Aug 2025 |
8-K: Regulation FD Disclosure; Other Events
GFH375 demonstrated an overall response rate (ORR) of 68.8% in non-small cell lung cancer (NSCLC) at the |
Loading...